ReNetX completes enrollment in spinal cord study

ReNetX Bio has reported successful completion of patient enrollment in Part 2 of its RESET study.

The RESET study (Part 2) is a multiple dose, double-blind, placebo-controlled study to confirm safety and tolerability, and to investigate the efficacy of AXER-204 with chronic cervical spinal cord injury.

According to the National Spinal Cord Injury Statistical Center, there are 300,000 people in the US living with chronic spinal cord injury, and 60% of those individuals have a cervical level injury resulting in quadriplegia. The lifelong cost of spinal cord injury is over $5M per patient depending on age and severity of injury, with no treatments available to date.